CGTLive®’s Weekly Rewind – August 22, 2025

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Iovance Biotherapeutics’ TIL Therapy Lifileucel Approved for Advanced Melanoma in Canada

Lifileucel has been approved in the US since February 2024.

2. Damien Maura, PhD, on AAV Capsids That Evade Neutralizing Antibodies

The senior scientist at Voyager Therapeutics discussed the company’s work on developing AAV capsids capable of overcoming patients’ preexisting immunity.

3. FDA Lifts Clinical Hold on Rocket’s Trial for Danon Disease Gene Therapy RP-A501

The hold was originally placed on the trial by the FDA on May 23, 2025, following the death of a patient treated in the study.

4. Bernie Owusu-Yaw, PhD, on Focused Ultrasound Mediated Delivery for AAV Gene Therapy

The postdoctoral research fellow at Brigham and Women's Hospital discussed research on focused ultrasound aimed at enhancing AAV delivery across the blood-brain barrier.

5. Great Ormond Street Hospital Tackling Chronic Granulomatous Disease With Gene Therapy in Phase 1/2 Trial

The nonrandomized, open-label clinical trial for pCHIM-p47, which launched on March 20, 2023, is taking place at Great Ormond Street Hospital in London.